Makary defends Replimune melanoma rejection again as FDA tensions build

RegulatoryrejectedNegative

AI Analysis

Summary

FDA Commissioner Marty Makary defended the agency's rejection of Replimune's melanoma program, characterizing criticism as "corporate spin" amid mounting pressure from industry and the White House.

Outcome Details

FDA rejected Replimune's melanoma application

Importance:7/10

Sentiment:

-0.70

FDA rejectionmelanomaregulatory tensionindustry pressure

Related Companies

$REPL

Read the original article

Published by BioSpace on May 6, 2026 11:18 AM

Read Original